Neuren Pharmaceuticals (ASX: NEU) announced today that Dr Clive Blower will join the leadership team as Vice-President: Product Development and Technical Affairs, based in Melbourne Australia, effective 25 August 2014. This appointment supports Neuren’s strategy to optimise the technical attributes, manufacturing process and commercial product supply of its lead drug NNZ-2566 as it progresses towards the final stages of development.

Clive is currently Chief Operating Officer of Acrux (ASX: ACR) where he has been a member of the senior management team for seven years. Clive was directly responsible for the Chemistry Manufacturing and Controls (CMC) aspects of the development of Axiron® through to submission of a marketing application to the US Food and Drug Administration (FDA), as well as the establishment of commercial product supply. He holds a Doctorate in Chemistry from Monash University and has over 20 years experience in all stages of drug development, from concept through to commercialisation.

Commenting on the appointment, Neuren Executive Chairman Richard Treagus said; “I am delighted that Clive has chosen to join the Neuren team at this very exciting time. He brings a very broad technical pharmaceutical knowledge and a rare level of hands-on experience interacting with global contract manufacturers and the FDA. I fully expect that Clive will make an immediate and strong contribution towards our CMC strategy for NNZ-2566 and NNZ-2591, as well as adding significantly to our capabilities and preparedness for dealing with global partners."

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile X Syndrome as well as acute neurological injuries. Neuren presently has a clinical stage molecule, NNZ-2566, in three Phase 2 clinical trials, as well as NNZ-2591 in pre-clinical development.

For more information, please contact:

Dr Richard Treagus, Executive Chairman
rtreagus@neurenpharma.com
Tel: +61 417 520 509